Olaf Stüve

21.2k total citations · 3 hit papers
251 papers, 11.5k citations indexed

About

Olaf Stüve is a scholar working on Pathology and Forensic Medicine, Oncology and Immunology. According to data from OpenAlex, Olaf Stüve has authored 251 papers receiving a total of 11.5k indexed citations (citations by other indexed papers that have themselves been cited), including 151 papers in Pathology and Forensic Medicine, 78 papers in Oncology and 77 papers in Immunology. Recurrent topics in Olaf Stüve's work include Multiple Sclerosis Research Studies (149 papers), Polyomavirus and related diseases (48 papers) and Peripheral Neuropathies and Disorders (44 papers). Olaf Stüve is often cited by papers focused on Multiple Sclerosis Research Studies (149 papers), Polyomavirus and related diseases (48 papers) and Peripheral Neuropathies and Disorders (44 papers). Olaf Stüve collaborates with scholars based in United States, Germany and Canada. Olaf Stüve's co-authors include Bernhard Hemmer, Bernd C. Kieseier, Scott S. Zamvil, Hans-Peter Hartung, Sawsan Youssef, Gary Cutter, Lawrence Steinman, Elliot M. Frohman, Jeffrey A. Cohen and Per Soelberg Sørensen and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Olaf Stüve

243 papers receiving 11.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease

2002 896 citations Olaf Stüve et al. profile →
The incidence and prevalence of psychiatric disorders in multiple sclerosis: A systematic review

2015 371 citations Olaf Stüve et al. Multiple Sclerosis Journal profile →
A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview

2015 296 citations Olaf Stüve et al. Multiple Sclerosis Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Olaf Stüve United States	57	6.4k	3.3k	2.6k	2.4k	1.9k	251	11.5k
Finn Sellebjerg Denmark	54	6.0k 0.9×	3.4k 1.0×	2.5k 1.0×	2.5k 1.0×	1.7k 0.9×	315	10.3k
Peter Rieckmann Germany	64	6.8k 1.1×	3.1k 0.9×	2.9k 1.1×	2.4k 1.0×	2.2k 1.2×	266	13.1k
Robert J. Fox United States	54	7.9k 1.2×	2.6k 0.8×	2.8k 1.1×	2.2k 0.9×	2.2k 1.2×	310	12.8k
Alasdair Coles United Kingdom	43	9.1k 1.4×	3.8k 1.1×	3.3k 1.3×	2.7k 1.1×	1.9k 1.0×	199	13.4k
Bruce Cree United States	61	8.3k 1.3×	2.7k 0.8×	3.5k 1.4×	1.8k 0.7×	3.2k 1.7×	279	13.0k
Jan Hillert Sweden	63	8.5k 1.3×	4.8k 1.4×	2.3k 0.9×	2.2k 0.9×	2.5k 1.3×	365	14.3k
Bernd C. Kieseier Germany	58	4.8k 0.8×	2.5k 0.7×	4.3k 1.6×	2.0k 0.8×	1.9k 1.0×	274	11.6k
Alastair Compston United Kingdom	45	6.1k 1.0×	3.3k 1.0×	1.7k 0.6×	1.5k 0.6×	2.9k 1.5×	128	12.0k
Manuel Comabella Spain	47	5.0k 0.8×	2.0k 0.6×	2.3k 0.9×	1.7k 0.7×	2.2k 1.2×	202	8.9k
Michael K. Racke United States	61	5.2k 0.8×	6.7k 2.0×	1.7k 0.6×	2.5k 1.0×	3.2k 1.7×	180	13.2k

Countries citing papers authored by Olaf Stüve

Since Specialization

Citations

This map shows the geographic impact of Olaf Stüve's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olaf Stüve with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olaf Stüve more than expected).

Fields of papers citing papers by Olaf Stüve

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Olaf Stüve. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olaf Stüve. The network helps show where Olaf Stüve may publish in the future.

Co-authorship network of co-authors of Olaf Stüve

This figure shows the co-authorship network connecting the top 25 collaborators of Olaf Stüve. A scholar is included among the top collaborators of Olaf Stüve based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Olaf Stüve. Olaf Stüve is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shirani, Afsaneh & Olaf Stüve. (2025). Glucagon‑like peptide‑1 receptor agonists in multiple sclerosis: therapeutic promise, challenges, and future directions. Expert Opinion on Investigational Drugs. 34(11). 929–941.

Spain, Rebecca, M. Mateo Paz Soldán, Mark S. Freedman, et al.. (2025). Lipoic Acid for Treatment of Progressive Multiple Sclerosis. Neurology. 106(1). e214454–e214454. 1 indexed citations

Stüve, Olaf, et al.. (2025). Tau in Multiple Sclerosis: A Review of Therapeutic Potential. Current Treatment Options in Neurology. 27(1). 1 indexed citations

Au, Kin Man, et al.. (2024). Multiple sclerosis treatments a review of current biomedical engineering approaches. Biomaterials. 313. 122807–122807. 5 indexed citations

Sguigna, Peter V., Rehana Z. Hussain, Kyle Blackburn, et al.. (2024). Cladribine tablets after treatment with natalizumab (CLADRINA) – rationale and design. Therapeutic Advances in Neurological Disorders. 17. 3 indexed citations

Montalbán, Xavier, Patrick Vermersch, Douglas L. Arnold, et al.. (2024). Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials. The Lancet Neurology. 23(11). 1119–1132. 32 indexed citations

Miller-Little, William A., Xing Chen, Vanessa Salazar, et al.. (2024). A T _H 17-intrinsic IL-1β–STAT5 axis drives steroid resistance in autoimmune neuroinflammation. Science Immunology. 9(95). eabq1558–eabq1558. 4 indexed citations

Shirani, Afsaneh, Olaf Stüve, & Anne H. Cross. (2023). Role of B Cells in Relapsing-Remitting and Progressive Multiple Sclerosis and Long-Term Effects of B Cell Depletion. Neurologic Clinics. 42(1). 137–153. 1 indexed citations

Manouchehri, Navid, Victor H. Salinas, Rehana Z. Hussain, & Olaf Stüve. (2023). Distinctive transcriptomic and epigenomic signatures of bone marrow-derived myeloid cells and microglia in CNS autoimmunity. Proceedings of the National Academy of Sciences. 120(6). e2212696120–e2212696120. 4 indexed citations

10.

Manouchehri, Navid, Afsaneh Shirani, Victor H. Salinas, et al.. (2022). Clinical trials in multiple sclerosis: past, present, and future. Neurologia i Neurochirurgia Polska. 56(3). 228–235. 4 indexed citations

11.

Manouchehri, Navid, Rehana Z. Hussain, Petra D. Cravens, et al.. (2021). CD11c ⁺ CD88 ⁺ CD317 ⁺ myeloid cells are critical mediators of persistent CNS autoimmunity. Proceedings of the National Academy of Sciences. 118(14). 14 indexed citations

12.

Goldman, Myla, et al.. (2020). Patient-specific factors modulate leukocyte response in dimethyl fumarate treated MS patients. PLoS ONE. 15(2). e0228617–e0228617. 18 indexed citations

13.

Caldito, Natalia Gonzalez, Afsaneh Shirani, Amber Salter, & Olaf Stüve. (2020). Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting Database. Multiple Sclerosis Journal. 27(7). 1066–1076. 37 indexed citations

14.

Zhao, Picheng, et al.. (2018). Presenilin1 regulates Th1 and Th17 effector responses but is not required for experimental autoimmune encephalomyelitis. PLoS ONE. 13(8). e0200752–e0200752. 5 indexed citations

15.

Raphael, Itay, et al.. (2014). Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future. Expert Review of Clinical Immunology. 11(1). 69–91. 45 indexed citations

16.

Hörste, Gerd Meyer zu, Anne K. Mausberg, Carsten Korth, Olaf Stüve, & Bernd C. Kieseier. (2010). Quinpramine - A promising compound for treating immune-mediated demyelination of the nervous system. Drug News & Perspectives. 23(5). 287–287. 4 indexed citations

17.

Stüve, Olaf. (2009). Knowns and unknowns in the future of multiple sclerosis treatment. Journal of the Neurological Sciences. 287. S30–S36. 16 indexed citations

18.

Stüve, Olaf, Petra D. Cravens, Elliot M. Frohman, et al.. (2008). Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology. 72(5). 396–401. 101 indexed citations

19.

Frohman, E., Fiona Costello, Olaf Stüve, et al.. (2008). Modeling axonal degeneration within the anterior visual system. UCL Discovery (University College London).

20.

Stüve, Olaf. (2008). The effects of natalizumab on the innate and adaptive immune system in the central nervous system. Journal of the Neurological Sciences. 274(1-2). 39–41. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact